Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

Giovany Orozco-Leal, Eugenie Evelynne Johnson, Sedighe Hosseinijebeli, Tomos Robinson, Tara Homer, Claire H. Eastaugh, Catherine Richmond, Louise Tanner, Nick Meader, Ryan Kenny, Sheila A. Wallace and Stephen Rice ()
Additional contact information
Giovany Orozco-Leal: Newcastle University
Eugenie Evelynne Johnson: Newcastle University
Sedighe Hosseinijebeli: Newcastle University
Tomos Robinson: Newcastle University
Tara Homer: Newcastle University
Claire H. Eastaugh: Newcastle University
Catherine Richmond: Tyne and Wear NHS Foundation Trust
Louise Tanner: Newcastle University
Nick Meader: Newcastle University
Ryan Kenny: Newcastle University
Sheila A. Wallace: Newcastle University
Stephen Rice: Newcastle University

PharmacoEconomics, 2024, vol. 42, issue 2, No 1, 133-136

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01328-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:2:d:10.1007_s40273-023-01328-w

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01328-w

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().